We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 13, 2020

Severe Thrombocytopenia as a Predictor of Survival and Response to Hypomethylating Agents in Myelodysplastic Syndromes

American Journal of Hematology

 

Additional Info

American Journal of Hematology
Severe Thrombocytopenia as a Predictor of Survival and Response to Hypomethylating Agents in Myelodysplastic Syndromes: A Latin-American Cohort Of 212 Patients
Am. J. Hematol 2020 Aug 30;[EPub Ahead of Print], C Lazzarino, J Arbelbide, S Schuster, R Crisp, J Gonzalez, R Tavares, MA Perusini, M Di Stefano, N Pintos, D Espinosa, M Pimentel, M Rosenhain, JC Serrano, A Enrico, M Iastrebner, C Belli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading